Solid Biosciences Inc
SLDB6.520USD
+0.290+4.65%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
507.80MCap. mercado
PérdidaP/E TTM
Más Datos de Solid Biosciences Inc Compañía
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Información de Solid Biosciences Inc
Símbolo de cotizaciónSLDB
Nombre de la empresaSolid Biosciences Inc
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoCumbo (Alexander)
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 26
Dirección500 Rutherford Avenue
CiudadCHARLESTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02129
Teléfono16173374680
Sitio Webhttps://www.solidbio.com/
Símbolo de cotizaciónSLDB
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoCumbo (Alexander)
Ejecutivos de Solid Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
219.15K
-129171.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
97.86K
-56665.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
77.59K
-41620.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
70.33K
-38883.00%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
60.21K
-37155.00%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+1860.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
219.15K
-129171.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
97.86K
-56665.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
77.59K
-41620.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
70.33K
-38883.00%
Desglose de ingresos
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mar., 18 de nov
Actualizado: mar., 18 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Otro
52.47%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Otro
52.47%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
38.87%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.48%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
1.13%
Bank and Trust
0.13%
Pension Fund
0.07%
Participación institucional
Actualizado: lun., 5 de ene
Actualizado: lun., 5 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
257
82.72M
106.17%
-17.41M
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
11.83M
15.19%
-73.11K
-0.61%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.15%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Sep 30, 2025
RA Capital Management, LP
5.81M
7.46%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
5.21%
-309.31K
-7.08%
Sep 30, 2025
Adage Capital Management, L.P.
4.00M
5.13%
-2.73M
-40.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.08M
3.96%
-281.70K
-8.37%
Sep 30, 2025
Vestal Point Capital, LP
2.98M
3.82%
+1.47M
+97.67%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.91M
3.74%
-264.27K
-8.31%
Sep 30, 2025
Citadel Advisors LLC
2.59M
3.33%
+69.40K
+2.75%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción0.52%
iShares Micro-Cap ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
